Keywords
Last Name
Institution

Nathan Graeme Dolloff

Title
InstitutionMedical University of South Carolina
DepartmentCell and Molecular Pharmacology and Experimental Therapeutics
AddressP.O. Box MSC 509
DD407
Drug Discovery Building - 70 President St.
Phone843-876-2204
Fax843-792-2475
vCardDownload vCard

    Collapse Overview 
    Collapse studies/trials
    Collapse overview
    Efforts in the Dolloff Laboratory are aimed at discovering and developing new targeted therapies for the treatment of incurable hematologic malignancies. The primary disease focus is Multiple Myeloma (MM) with a general interest in cytogenetically related B and plasma cell cancers that include non-Hodgkins Lymphoma, plasma cell leukemia, and others. Major objectives of the lab are to identify and validate new molecular targets and establish high throughput drug screening assays for screening large chemical libraries. Lead compounds that are discovered are then used as tools to better understand the biology of new targets and/or are selected for further drug development toward the ultimate goal of clinical translation.
    Collapse keywords
    Targeting IgH Gene Enhancers, Overcoming Proteasome Inhibitor Resistance, Targeting Redox Regulation

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Hurst KE, Lawrence KA, Reyes Angeles L, Ye Z, Zhang J, Townsend DM, Dolloff N, Thaxton JE. Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors. Cells. 2019 Nov 26; 8(12). PMID: 31779147.
      View in: PubMed
    2. Robinson RM, Reyes L, Duncan RM, Bian H, Strobel ED, Hyman SL, Reitz AB, Dolloff NG. Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor. Eur J Med Chem. 2020 Jan 15; 186:111906. PMID: 31787362.
      View in: PubMed
    3. Pierce MR, Robinson RM, Ibarra-Rivera TR, Pirrung MC, Dolloff NG, Bachmann AS. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leuk Res. 2020 Jan; 88:106271. PMID: 31778912.
      View in: PubMed
    4. Dolloff NG. Discovery platform for inhibitors of IgH gene enhancer activity. Cancer Biol Ther. 2019; 20(4):571-581. PMID: 30481117.
      View in: PubMed
    5. Robinson RM, Reyes L, Duncan RM, Bian H, Reitz AB, Manevich Y, McClure JJ, Champion MM, Chou CJ, Sharik ME, Chesi M, Bergsagel PL, Dolloff NG. Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia. 2019 04; 33(4):1011-1022. PMID: 30315229.
      View in: PubMed
    6. Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017 May 30; 8(22):35863-35876. PMID: 28415782.
      View in: PubMed
    7. Dolloff NG. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Adv Cancer Res. 2015; 127:191-226. PMID: 26093901.
      View in: PubMed
    8. Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia. 2014 Nov; 28(11):2263-7. PMID: 25005244.
      View in: PubMed
    9. Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS. CDK1 stabilizes HIF-1a via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle. 2013 Dec 01; 12(23):3689-701. PMID: 24189531.
      View in: PubMed
    10. Xu HN, Feng M, Moon L, Dolloff N, El-Deiry W, Li LZ. REDOX IMAGING OF THE p53-DEPENDENT MITOCHONDRIAL REDOX STATE IN COLON CANCER EX VIVO. J Innov Opt Health Sci. 2013 Jul; 6(3). PMID: 26207147.
      View in: PubMed
    11. Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013 Jun; 12(6):1140-50. PMID: 23536725.
      View in: PubMed
    12. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 06; 5(171):171ra17. PMID: 23390247.
      View in: PubMed
    13. Dolloff NG, Talamo G. Targeted therapy of multiple myeloma. Adv Exp Med Biol. 2013; 779:197-221. PMID: 23288641.
      View in: PubMed
    14. Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012 Nov; 11(11):2321-30. PMID: 22964485.
      View in: PubMed
    15. Talamo G, Dolloff NG, Sharma K, Zhu J, Malysz J. Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents. Rare Tumors. 2012 Jun 26; 4(3):e39. PMID: 23087795.
      View in: PubMed
    16. Talamo G, Rakszawski KL, Rybka WB, Dolloff NG, Malysz J, Berno T, Zangari M. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma. Eur J Haematol. 2012 Aug; 89(2):145-50. PMID: 22540279.
      View in: PubMed
    17. Finnberg NK, Hart LS, Dolloff NG, Rodgers ZB, Dicker DT, El-Deiry WS. High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. Am J Pathol. 2011 Nov; 179(5):2169-76. PMID: 21975022.
      View in: PubMed
    18. Dolloff NG, Ma X, Dicker DT, Humphreys RC, Li LZ, El-Deiry WS. Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biol Ther. 2011 Aug 15; 12(4):349-56. PMID: 21757995.
      View in: PubMed
    19. Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51. PMID: 21725213.
      View in: PubMed
    20. Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38. PMID: 21725212.
      View in: PubMed
    21. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle. 2011 Jul 15; 10(14):2331-8. PMID: 21720213.
      View in: PubMed
    22. Faltas B, Zeidan A, Peters K, Das A, Joudeh J, Navaraj A, Dolloff NG, Harvey HA, Jiang Y, Allen JE, Dicker DT, El Deiry WS. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J Clin Oncol. 2011 Jul 20; 29(21):2946-7; author reply 2947-8. PMID: 21690466.
      View in: PubMed
    23. Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med. 2011 Jun 08; 3(86):86ra50. PMID: 21653830.
      View in: PubMed
    24. Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, El-Deiry WS. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3ß and CDK1. Cancer Res. 2011 Aug 01; 71(15):5265-75. PMID: 21646472.
      View in: PubMed
    25. Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, Loughran TP, Epner E. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):464-8. PMID: 21156463.
      View in: PubMed
    26. Talamo G, Castellani W, Dolloff NG. Prozone effect of serum IgE levels in a case of plasma cell leukemia. J Hematol Oncol. 2010 Sep 10; 3:32. PMID: 20828419.
      View in: PubMed
    27. Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle. 2009 Dec 15; 8(24):4168-75. PMID: 20054236.
      View in: PubMed
    28. Russell MR, Jamieson WL, Dolloff NG, Fatatis A. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene. 2009 Jan 22; 28(3):412-21. PMID: 18850002.
      View in: PubMed
    29. Yang W, Dolloff NG, El-Deiry WS. ERK and MDM2 prey on FOXO3a. Nat Cell Biol. 2008 Feb; 10(2):125-6. PMID: 18246039.
      View in: PubMed
    30. Dolloff NG, Russell MR, Loizos N, Fatatis A. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res. 2007 Jan 15; 67(2):555-62. PMID: 17234763.
      View in: PubMed
    31. Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, Meucci O, Fatatis A. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene. 2005 Oct 13; 24(45):6848-54. PMID: 16007172.
      View in: PubMed
    32. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 2004 Jul 15; 64(14):4693-8. PMID: 15256432.
      View in: PubMed
    Dolloff's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description